Quest Diagnostics Incorporated (DGX) analyst actions
Rating and price-target actions on DGX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DGX overview →
1 measured DGX analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| First PFAS "Forever Chemicals" Consumer-Initiated Blood Test with Physician Consult Launches on questhealth.com | Press release | -0.23% | +2.79% |
Keep exploring
More DGX: earnings → · SEC filings → · DGX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Dr. Reddy's Laboratories Ltd (RDY) | 528 | 0.00% | 47% |
| LOXO ONCOLOGY (LOXO) | 526 | 0.00% | 49% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 524 | -0.32% | 46% |
| STAAR Surgical Company (STAA) | 522 | -0.21% | 44% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.